Tumor angiogenesis

Česká verzia

Authors: Š. Lukešová ¹; O. Kopecký ¹; J. Dvořák ² ; D. Hlávková ¹; V. Vroblová ¹
Authors place of work: Ústav klinické imunologie a alergologie Lékařské fakulty UK a FN Hradec Králové, přednosta MUDr. Otakar Kopecký, CSc. ¹; Klinika onkologie a radioterapie Lékařské fakulty UK a FN Hradec Králové, přednosta doc. MUDr. Jiří Petera, Ph. D. ²
Published in the journal: Vnitř Lék 2006; 52(9): 797-800
Category: Review

Summary

Angiogenesis have shown a major role in tumor growth and metastasis formation. For tumor growth beyond the size 1 - 2 mm³, angiogenesis must be started to form vascular supply of tumor cells. Angiogenesis is a complex process, involving degradation of the basement membrane of preexisting vessel, proliferation of endothelial cells towards the angiogenetic stimulus, maturation of endothelial cells with formation of luminized capillary, and finally formation of a functional vessel, surrounded by basement membrane and pericytes. Angiogenesis is regulated by numerous angiogenic and anti-angiogenic factors. Hypoxia is a significant stimulus for angiogenesis. For many cancers the extent of vascularisation is a negative prognostic indicator signifying aggressive disease and increased potential for metastasis.

Key words:
angiogenesis - tumor growth - metastasis - VEGF (vascular endothelial growth factor) - HIF (hypoxia inducible factor)

Zdroje

1. Akagi Y, Liu W, Zebrowski B et al. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-growth factor-l. Cancer Res 1998; 58: 4008-4014.

2. Baltaci S, Orhan D, Gögüs C et al. Thrombospondin-1, vascular endothelial growth factor expression and microvessel density in renal cel carcinoma and their relationship with multifocality. Eur Urol 2003; 44: 76-81.

3. Bamias A, Dimopoulos MA. Angiogenesis in human cancer: implications in cancer therapy. Eur J Int Med 2003; 14: 459-469.

4. Beecken WD, Bentas W, Glienke W et al. Serum angiogenic activity: diagnostic relevance in renal cell carcinoma. Eur Urol 2002; 42: 364-369.

5. Bischoff J. Approaches to studying cell adhesion molecules in angiogenesis. Trends Cell Biol 1995; 5: 69-73.

6. Brooks PC, Montgomery AMP, Rosenreld M et al. Integrin avb3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79: 1157-1164.

7. Carmeliet P, Dor Y, Herbert JM et al. Role of HIF-I in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-490.

8. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-2490.

9. Eleutherakis-Papaiakovou V, Karali M, Kokkonouzis I et al. Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach. Leuk Lymphoma 2003; 44: 937-948.

10. Folkman J. Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel MA et al (ed). The Molecular Basis or Cancer. Philadelphia: WB Saunders 1995: 206-232.

11. Gasparini G, Brooks PC, Biganzoli E et al. Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res 1998; 4: 2625-2634.

12. Inoue K, Kamada M, Slaton JW et al. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 2002; 8: 1863-1870.

13. Jacobsen J, Grankvist K, Rasmuson T et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU International 2004; 93: 297-302.

14. Jewell UR, Kvietikova I, Scheid A et al. Induction of HIF-I in response to hypoxia is instantaneous. FASEB J 2001; 15: 1312-1314.

15. Kerbel R, Folkman J Clinical translation or angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-739.

16. Klener P. Angiogeneze a nádorová onemocnění. Remedia 2002; 12: 2-8.

17. Klener P. Klinická onkologie. Praha: Galén 2002; 66-71.

18. Klener P. Význam angiogeneze u nádorových onemocnění a možnosti jejího ovlivnění. Forum Medicinae 1999; 2: 54-61.

19. Levy AP, Levy NS, Wegner S et al. Transcriptional regulation of the rat vascular endothelial growth factor by hypoxia. J Biol Chem 1995; 270: 13333-13340.

20. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000; 5 (Suppl 1): 3-10.

21. Mukhopadhyay D, Datta K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Seminars Cancer Biol 2004; 14: 123-130.

22. O´Byrne KJ, Dobbs N, Propper D et al. Vascular endothelial growth factor platelet counts, and prognosis in renal cancer. Lancet 1999; 353: 1494-1495.

23. Or R, Feferman R, Shoshan S. Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polivinyl alcohol sponges in guinea pigs. Exp Hematol 1998; 26: 217-221.

24. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996; 380: 364-366.

25. Ryška A. Angiogeneze v nádorech. Část I.: Úloha v určování biologických vlastností nádoru; faktory ovlivňující vznik a vývoj angiogeneze. Čes Slov Patol 2000; 36: 26-31.

26. Salceda S, Cam J. Hypoxia-inducible factor I (HIF-I) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redoxinduced changes. J Biol Chem 1997; 272: 22642-22647.

27. Sasaki H, Yukiue H, Kobayashi Y et al. Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg Today 2001; 31: 1038-1040.

28. Sholley MM, Ferguson GP, Seibel HR et al. Mechanisms of neovasculaization. Lab Invest 1984; 51: 624-634.

29. Slaton JW, Inoue K, Perrotte P et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol 2001; 158: 735-743.

30. Song KH, Song J, Jeong GB et al. Vascular endothelial growth factor - its relation to neovascularization and their significance as prognostic factors in renal cell carcinoma. Yonsei Med J 2001; 42: 539-546.

31. Stromblad S, Cheresh DA. Cell adhesion and angiogenesis. Trends Cell Biol 1996; 6: 462-467.

32. Takayashi Y, Clearly KR, Mai M et al. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 1996; 2: 1679-1684.

33. Takayashi Y, Kitadai Y, Bucana CD et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 72: 319-324.

34. Talač R, Žaloudík J, Pačovský Z et al. Neovaskularizace u solidních nádorů. Klin Onkol 1995; 6: 165-167.

35. Wang GL, Jiang BH, Rue EA et al. Hypoxia-inducible factor I is a basic-helix -loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514.

36. Weidner N, Sample JP, Welch WR et al. Tumor angiogenesis and metastasis-correlation in invasive breast cancer. N Engl J Med 1991; 324: 1.

37. Yagasaki H, Kawata N, Takimoto Y et al. Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol 2003; 10: 220-227.

38. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213.

39. Zhang X, Yamashita M, Uetsuki H et al. Angiogenesis in renal cell carcinoma: Evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases. Int J Urol 2002; 9: 509-514.